Clinical Trials

19 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03252938 2026-02-19

INSIGHT

Phase EARLY_PHASE1 Active not recruiting

83 enrolled

GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

22 enrolled

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03944941 2026-02-05

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

60 enrolled

Skin Neoplasms

NCT03391479 2025-12-18

A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

25 enrolled

Phase 1/2 Active not recruiting

Neoplasm Metastasis, Penile Neoplasms

NCT04266912 2025-11-25

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

23 enrolled 11 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT03217747 2025-10-23

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Phase 1/2 Active not recruiting

173 enrolled 28 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

Phase 3 Active not recruiting

220 enrolled 11 charts

Breast

Breast Neoplasms

NCT03271372 2025-09-17

ADAM

101 enrolled

Carcinoma, Merkel Cell

NCT04387084 2025-09-05

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

10 enrolled

Skin Neoplasms

NCT04792073 2025-08-11

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

18 enrolled

Neoplasm Metastasis, Carcinoma, Merkel Cell

NCT02912572 2025-07-10

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

106 enrolled 16 charts

Gynecologic

Endometrial Neoplasms

NCT03414658 2025-07-02

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Phase 1/2 Active not recruiting

100 enrolled 15 charts

Breast

Breast Neoplasms

NCT03964532 2025-05-21

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

24 enrolled

Breast

Breast Neoplasms

NCT02999087 2025-05-07

REACH

Phase 3 Active not recruiting

707 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03498378 2025-04-03

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

24 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT04291885 2025-04-03

I-MAT

Phase 3 Active not recruiting

122 enrolled

DermatologicEndocrineNET

Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04637594 2025-01-15

IMAGINE

3 enrolled

Carcinoma, Transitional Cell

NCT03494322 2024-05-08

EACH

130 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT05289856 2024-03-07

Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)